Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058551 | 0.96 | PTGER4 (0.46) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL10058532 | 0.95 | PTGER4 (0.45) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL10058520 | 0.92 | PTGER4 (0.49) | PTGER4CYP1A2CYP2D6L3MBTL1ALDH1A1 | |
| SCHEMBL10058516 | 0.92 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL9606761 | 0.89 | PTGER4 (0.61) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL10058545 | 0.89 | PTGER4 (0.54) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL8591107 | 0.88 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL12002019 | 0.87 | PTGER4 (0.43) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL10058550 | 0.86 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL9606836 | 0.86 | PTGER4 (0.53) | PTGER4CYP1A2CYP2D6SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| WO-2007088190-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885CYP1A2 284/4885CYP2D6 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.